It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Primary liver cancer mainly includes the following four types: hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), hepatoblastoma (HB), and combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CCA). Recent studies have indicated that there are differences in cancer stem cell (CSC) properties among different types of liver cancer. Liver cancer stem cells (LCSCs), also called liver tumor-initiating cells, have been viewed as drivers of tumor initiation and metastasis. Many mechanisms and factors, such as mitophagy, mitochondrial dynamics, epigenetic modifications, the tumor microenvironment, and tumor plasticity, are involved in the regulation of cancer stemness in liver cancer. In this review, we analyze cancer stemness in different liver cancer types. Moreover, we further evaluate the mechanism of cancer stemness maintenance of LCSCs and discuss promising treatments for eradicating LCSCs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Tangdu Hospital, Air Force Military Medical University, Department of General Surgery, Xi’an, China (GRID:grid.460007.5) (ISNI:0000 0004 1791 6584); The 75th Group Army Hospital, Department of General Surgery, Dali, China (GRID:grid.460007.5)
2 Tangdu Hospital, Air Force Military Medical University, Department of Pain Treatment, Xi’an, China (GRID:grid.460007.5) (ISNI:0000 0004 1791 6584)
3 The 75th Group Army Hospital, Department of Obstetrics and Gynecology, Dali, China (GRID:grid.460007.5)
4 Xijing Hospital of Digestive Diseases, Air Force Military Medical University, State Key Laboratory of Cancer Biology and National Clinical Research Center for Digestive Diseases, Xi’an, China (GRID:grid.417295.c) (ISNI:0000 0004 1799 374X)
5 the First Affiliated Hospital of Zhejiang University, Department of General Surgery, Hangzhou, China (GRID:grid.452661.2) (ISNI:0000 0004 1803 6319)
6 Clinical Medical Research Center, The 75th Group Army Hospital, Dali, China (GRID:grid.452661.2)
7 Zhengzhou University, Department of Anorectal Surgery, The First Affiliated Hospital, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846)
8 the 74th group army hospital, Department of General Surgery, Guangzhou, China (GRID:grid.207374.5)
9 Tangdu Hospital, Air Force Military Medical University, Department of General Surgery, Xi’an, China (GRID:grid.460007.5) (ISNI:0000 0004 1791 6584)